Navigation Links
Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down

For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects, according to a 20-year follow-up of a randomized trial, which appears in the January 19 issue of the Journal of the National Cancer Institute.

The British Columbia randomized radiation therapy trial was designed to determine the effect on survival of the addition of locoregional radiation therapy (radiation to the lymph nodes and chest wall) to a course of chemotherapy after radical mastectomy in premenopausal women with lymph node–positive breast cancer. Between 1979 and 1986, 318 patients were randomly assigned to receive no radiation therapy or to receive radiation. A 15-year follow-up found that radiation therapy was associated with improved breast cancer survival but not with overall survival.

In this 20-year follow-up of the British Columbia trial, Joseph Ragaz, M.D., of McGill University Health Center in Montreal, and colleagues found that the chemotherapy and radiation regimen, compared with chemotherapy alone, was associated with improvement in all end points analyzed. This included a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared with chemotherapy alone. In addition, long-term toxic effects, including cardiac deaths, were acceptable for both groups of patients.

"Our results, and those from other groups, confirm that in situations where residual disease remains, adjuvant chemotherapy alone in high-risk breast cancer patients is suboptimal and that the addition of locoregional radiation therapy is important to achieve the highest cure rate," the authors write.

In an editorial, Timothy Whelan, B.M., B.Ch., and Mark Levine, M.D., of the Juravinski Cancer Centre in Hamilton, Ontario, discuss the use of locoregional radiation therapy in breast cancer patients and note that fewer clinicians accept its use in moderate-risk patients. "Because uncertainties continue about the effectiveness of locoregional radiation therapy after mastectomy in moderate-risk patients, we strongly urge that a randomized controlled trial be mounted to resolve these uncertainties," they write.


'"/>

Source:


Related biology news :

1. Novel technology detects human DNA mutations
2. Novel antiviral technology inhibits RSV infection in mice
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
5. Discovery Could Lead To Novel Approaches In HIV Treatment
6. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
7. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
8. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
9. Novel live reporting system to track cells
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2019)... ... December 04, 2019 , ... NDA Partners Chairman Carl ... toxicology expert with more than 20 years of experience working in the biopharmaceutical ... has extensive experience with a variety of biologic modalities including monoclonal antibodies, bi-specific ...
(Date:11/27/2019)... ... November 26, 2019 , ... Personalized Stem Cells, Inc ... by the Arthritis Foundation and hosted by Dr. Steven Sampson and Dr. Danielle Aufiero ... place on October 23, 2019, highlighted the ongoing efforts to promote research, educate the ...
(Date:11/19/2019)... HERCULES, Calif. (PRWEB) , ... November 19, 2019 ... ... for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and ... announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring ...
Breaking Biology News(10 mins):
(Date:12/6/2019)... ... December 06, 2019 , ... ... Inc. has received FDA 510(k) clearance for its latest CAPERE® Thrombectomy System ... data suggests the CAPERE® offers great benefits for first-in-line treatment for nonsurgical ...
(Date:12/4/2019)... POWAY, Calif. (PRWEB) , ... December 03, 2019 , ... ... went non-weightbearing lame on his right front leg. After several weeks of medical management, ... Dr. Mark Martinelli of California Equine Orthopedics . Results revealed Jesse had a ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... The technology ... than a human hair, but its potential impact on the pharmaceutical industry could be ... professor of biological and chemical engineering at South Dakota School of Mines & ...
(Date:11/22/2019)... ... November 22, 2019 , ... Modality ... step-by-step cold chain validation guide to meet and exceed increasingly stringent regulatory ... chain biopharmaceutical industry leaders, the September 19, 2019 webinar was well received ...
Breaking Biology Technology: